Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26200032 | 0.86 | USP30 (0.47) | USP30HPGDRECQLEPHX1ALDH1A1 | |
| SCHEMBL31634070 | 0.86 | USP30 (0.47) | USP30HPGDRECQLEPHX1CYP2C9 | |
| SCHEMBL15406922 | 0.85 | USP30 (0.46) | USP30HPGDRECQLEPHX1CYP2C9 | |
| SCHEMBL15406923 | 0.85 | USP30 (0.46) | USP30HPGDRECQLEPHX1CYP2C9 | |
| SCHEMBL7881349 | 0.83 | EPHX1 (0.52) | USP30HPGDEPHX1CYP2C9HSD11B1 | |
| SCHEMBL2281041 | 0.83 | HPGD (0.48) | USP30HPGDRECQLEPHX1ALDH1A1 | |
| SCHEMBL27427859 | 0.83 | HPGD (0.48) | USP30HPGDRECQLEPHX1ALDH1A1 | |
| SCHEMBL27427855 | 0.83 | HPGD (0.48) | USP30HPGDRECQLEPHX1ALDH1A1 | |
| SCHEMBL18502915 | 0.83 | HPGD (0.48) | USP30HPGDRECQLEPHX1ALDH1A1 | |
| SCHEMBL26172102 | 0.83 | HPGD (0.48) | USP30HPGDRECQLEPHX1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | BEIJING TIDE PHARMACEUTICAL CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| WO-2023122778-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023122778-A1 | PYRIDAZINONE DERIVATIVES USEFUL AS T CELL ACTIVATORS | GOSSAMER BIO SERVICES, INC. (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-4166556-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | Beijing Tide Pharmaceutical Co., Ltd. (CN) | 2023-04-19 | — | — | EP | disclosed |
| EP-2872501-B1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING SA (CH) | 2016-06-01 | — | — | EP | disclosed |
| EP-2872501-B1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING SA (CH) | 2016-06-01 | — | — | EP | disclosed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | disclosed |
| US-9216991-B2 | Pyrimidine pyrazolyl derivatives | ARES TRADING S.A. (CH) | 2015-12-22 | — | — | US | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2015-05-21 | — | — | US | disclosed |
| EP-2872501-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | Ares Trading S.A. (CH) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014008992-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2014-01-16 | — | — | WO | disclosed |
| WO-2014008992-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | ARES TRADING S.A. (CH) | 2014-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271968-A1 | PYRAZOLOPYRIMIDINE COMPOUND USED AS ATR KINASE INHIBITOR | ATR, CHEK1, CHEK2 | USP30 1816/4885HPGD 2051/4885RECQL 110/4885 |
| US-20150141396-A1 | PYRIMIDINE PYRAZOLYL DERIVATIVES | DPYD, TYMS, DHFR | USP30 4081/4885HPGD 267/4885RECQL 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.